Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies.

Abstract

Hyperuricemia is a common manifestation of lymphoid malignancies at diagnosis or after the start of chemotherapy. When accompanied by other metabolic abnormalities and/or organ failure, hyperuricemia may be a manifestation of tumor lysis syndrome (TLS). Patients at particularly high risk of such complications include those with acute lymphoblastic leukemia and advanced stage non-Hodgkin's lymphoma. Conventional measures to prevent hyperuricemia and TLS are comprised of hydration, alkalinization of body fluids, and administration of allopurinol. Although these measures are usually effective in preventing or managing hyperuricemia, approximately 20% of patients at high risk of TLS require dialysis, and many cannot receive chemotherapy as planned. Rasburicase, a recombinant form of the enzyme urate oxidase, has recently become available and may further reduce the morbidity of hyperuricemia and TLS. In this review, we provide an overview of hyperuricemia and TLS and discuss the impact of rasburicase in the overall management of these complications.

• Authors: Raul C Ribeiro, Ching-Hon Pui
• Journal: Clinical lymphoma (Clin Lymphoma) Vol. 3 Issue 4 Pg. 225-32 (Mar 2003) ISSN: 1526-9655 [Print] United States
• PMID: 12672271 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review)

Chemical References

• Recombinant Proteins
• rasburicase
• Urate Oxidase

Topics

• Clinical Trials as Topic
• Humans
• Hyperuricemia (etiology, prevention & control)
• Lymphoma (complications)
• Recombinant Proteins (therapeutic use)
• Risk Factors
• Tumor Lysis Syndrome (etiology, prevention & control)
• Urate Oxidase (therapeutic use)